AHAlycia Hatashima

Alycia Hatashima

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alycia Hatashima has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Mazyar Shadman

    Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA

    2 shared publications
  • Abberly Lott Limbach

    Department of Pathology, The Ohio State University and Arthur G. James Cancer Center, Columbus, Ohio, USA

    1 shared publication
  • Bhavana Konda

    Division of Medical Oncology, Department of Internal Medicine, The Ohio State University and Arthur G. James Cancer Center, Columbus, Ohio, USA

    1 shared publication
  • Brianna Archambeau

    Department of Pharmacy, The Ohio State University and Arthur G. James Cancer Center, Columbus, Ohio, USA

    1 shared publication
  • Eric M McLaughlin

    Department of Biomedical Informatics, Center for Biostatistics

    1 shared publication
  • Heather Armbruster

    Department of Pharmacy, The Ohio State University and Arthur G. James Cancer Center, Columbus, Ohio, USA

    1 shared publication

Latest Publications

  • Open Access

    Chimeric Antigen Receptor-T Cells in the Modern Era of Chronic Lymphocytic Leukemia Treatment

    by Alycia Hatashima, Mazyar Shadman, Vikram Raghunathan

    Pathway inhibitors targeting Bruton tyrosine kinase (BTK) and B-cell lymphoma-2 (BCL-2) have dramatically changed the treatment landscape for both treatment-naïve and relapsed/refractory chronic lymphocytic leukemia (CLL). However, with increased utilization, a growing number of patients will experience progressive disease on both agents. This subgroup of “double refractory” patients has limited treatment options and poor prognosis. Chimeric antigen receptor (CAR)-T cells have transformed the treatment of relapsed/refractory B-cell malignancies. Although the earliest success of CAR-T cell therapy was in CLL, the clinical application of this modality has lagged until the recent approval of the first CAR-T cell product for CLL. In this review, we describe the current treatment options for upfront and subsequent therapies and the unmet need for novel agents highlighted by the burgeoning role and challenges of CAR-T cell therapy.

  • BTK inhibitors: moving the needle on the treatment of chronic lymphocytic leukemia

    by Alycia Hatashima, Mazyar Shadman

    Bruton's tyrosine kinaseinhibitors (BTKis) changed the trajectory of upfront and relapsed/refractorychronic lymphocytic leukemia (CLL) treatment. However, BTKis are plagued by aspectrum of toxicities. Zanubrutinib was developed to circumvent challengeswith prolonged tolerability by increasing BTK selectivity and maximizingefficacy through pharmacokinetic/pharmacodynamic optimization. However, withthe availability of ibrutinib, acalabrutinib, and zanubrutinib, limited dataexists to guide sequencing of BTKi therapy in the relapsed/refractory setting. We review the firsthead-to-head trial (ALPINE) of zanubrutinib versus ibrutinib for the treatmentof relapsed/refractory CLL and compare zanubrutinib's clinical efficacy andtoxicities, including in patients with del(17p) and/or TP53 mutations to ibrutinib and acalabrutinib. Zanubrutinibrepresents one of the new standards of care for relapsed/refractory CLL basedon superior progression free survival and response rates over ibrutinib. Whilezanubrutinib is associated with fewer cardiac toxicities, similar rates ofneutropenia and hypertension are noted. Ongoing studies are pushing theenvelope, utilizing targeted drug combinations and minimal residual diseasemarkers as well as receptor tyrosine kinase-like orphan receptor 1 inhibitors, chimericantigen receptor T-cells and novel BTK degraders. However, zanubrutinibrepresents a strong contender in the arsenal of treatment options forrelapsed/refractory CLL.


  • An Evaluation of Clinical Efficacy of Immune Checkpoint Inhibitors for Patients with Anaplastic Thyroid Carcinoma

    by Alycia Hatashima, Brianna Archambeau, Heather Armbruster, Menglin Xu, Manisha H Shah, Bhavana Konda, Abberly Lott Limbach, Vineeth Sukrithan

    Background: Anaplastic thyroid carcinoma (ATC) is an aggressive thyroid malignancy that is associated with poor prognosis. Current treatment options include surgery, radiation, cytotoxic chemotherapy, and multikinase inhibitor therapy. The role of immunotherapy in ATC is an area of active interest and recent evidence suggests that it may be a potentially effective treatment option. Methods: We report a case series of 13 patients with locally advanced or metastatic unresectable ATC who received immune checkpoint inhibitor therapy (pembrolizumab or nivolumab) at a single institution. Results: The patients' median age was 70 years, 54% (7/13) were male, and 85% (11/13) had stage IVC disease with lungs and lymph nodes being the most common sites of metastases. Ten patients had tumor tissue available for programmed death-ligand 1 (PD-L1) expression testing, all of which were positive for PD-L1, and seven of these patients also had a BRAF V600E mutation. The median progression-free survival was 1.9 months and median overall survival (OS) was 4.4 months. The objective response rate was 16% (2/13). Two patients had partial response (PR), and three patients had durable stable disease. Among patients with a clinical benefit, after a median follow-up of 13.5 months, median OS had not been reached (range 4+ to 29+ months). Responses were ongoing in four subjects. The one-year survival rate was 38% (5/13). Six patients (46%) experienced an immune-related adverse event, and 15% (2/13) experienced a grade 3 or higher adverse event, including one patient with grade 5 immune checkpoint-related thyroiditis. Conclusions: Immune checkpoint blockade was well tolerated with a toxicity profile consistent with published literature on PD-1/PD-L1-targeting therapies. For ATC patients, immune checkpoint inhibition may represent an effective treatment option with robust sustained responses seen in a subset of patients.


  • First-line gemcitabine plus nab-paclitaxel versus FOLFIRINOX for metastatic pancreatic cancer in a real-world population

    by Alycia Hatashima, Matthew J Arango, Joshua Reardon, Tracelyn Freeman, Terence Williams, Eric M McLaughlin, Laith Abushahin

    Aim: To compare the overall survival (OS) among patients who received first-line modified gemcitabine plus nab-paclitaxel (G/nab-P) or 5-fluorouracil, leucovorin, irinotecan and oxaliplatin (mFOLFI... Plain language summary Pancreatic cancer that has spread to other parts of the body cannot be cured and patients usually have a limited time to live after diagnosis. It is therefore important to ch...